AOD-9604 in Mexico: C-terminal fragment of hGH (177-191) in lipolytic research

EXOMA Scientific Team · Publicado el 24 de mayo de 2026 · Actualizado el 18 de septiembre de 2026

AOD-9604 is a modified fragment of residues 177-191 of the C-terminal end of human growth hormone (hGH). Lipolytic research without activation of the GH receptor.

Executive summary

AOD-9604 (Anti-Obesity Drug 9604, CAS 221231-10-3, molecular formula C78H123N23O23S2, molecular weight 1815.08 g/mol) is the object of growing interest in preclinical research for its lipolytic activity characterized in preclinical models without activation of the GH receptor. This technical guide brings together molecular characterization, mechanism of action, bibliographic evidence with DOI/PubMed, and handling considerations for research use only.

Regulatory notice. This material is exclusively for in vitro and preclinical research use. It does not constitute a clinical or therapeutic recommendation.

What is AOD-9604?

AOD-9604 (also known as Tyr-hGH 177-191) is a synthetic analog of the C-terminal fragment of human growth hormone (hGH), corresponding to residues 177-191 with the addition of an N-terminal tyrosine to facilitate its synthesis and radiolabeling. Unlike complete hGH, AOD-9604 does not bind the GH receptor nor induce IGF-1-mediated responses.

Key molecular data

Mechanism of action

Its lipolytic mechanism has been characterized in preclinical models through activation of hormone-sensitive lipase and increased fatty-acid oxidation in adipocytes, without the hypertrophic effects of the N-terminal fragment of hGH.

The mechanistic characterization available in the indexed literature (PubMed, Web of Science) allows AOD-9604 to be categorized as an object of high research interest in its category. The most highly cited publications are reproduced in the section Bibliographic evidence below.

Documented lines of research

The available preclinical literature addresses mainly:

1. Pharmacokinetic characterization: in vivo studies in murine and porcine models on absorption, distribution, metabolism, and excretion of the analog.
2. Receptor mechanisms: competitive binding assays with radioligands to map affinity and selectivity for target receptors.
3. Animal efficacy models: preclinical assays on the phenotypic effect attributable to the peptide in models of the pathology under study.
4. In vitro stability and formulation: evaluation of the chemical and biological stability of the peptide under different storage and reconstitution conditions.

For an up-to-date systematic review, the researcher is advised to consult the PubMed, Google Scholar and Web of Science databases using the terms AOD-9604 and Anti-Obesity Drug 9604.

Bibliographic evidence

• Heffernan M, Summers RJ, Thorburn A, 2001 — Endocrinology. Effects of hGH and its lipolytic fragment (AOD9604) on lipid metabolism after chronic treatment. PubMed: 11713213
• Ng FM, Sun J, Sharma L, 2000 — Horm Res. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. PubMed: 11146367

Handling, reconstitution, and storage

Receipt and verification. Each lyophilized vial of AOD-9604 is shipped with its corresponding certificate of analysis (COA) issued by Chromasys, which includes identity by mass spectrometry, purity by reverse-phase HPLC, peptide content by amino acid analysis, residual acetate/TFA, residual water by Karl Fischer and endotoxins by LAL.

Standard reconstitution (research protocol). The standard procedure for sterile reconstitution is as follows:

1. Disinfect with isopropyl alcohol the rubber stoppers of the lyophilized AOD-9604 vial and of the vial of bacteriostatic water (BAC).
2. Aspirar el volumen calculado de BAC con jeringa de insulina estéril (consultar la EXOMA reconstitution calculator).
3. Inject the solvent slowly, resting the needle against the inner wall of the vial — never directly onto the lyophilized powder, to avoid aggregation and denaturation.
4. Gently roll the vial between your fingers until a clear solution is obtained. Never shake.
5. Store the reconstituted vial refrigerated (2–8 °C) protected from light. Avoid freeze-thaw cycles.

Storage of the lyophilizate. Refrigerated at 2–8 °C protected from light until the retest date indicated in the batch's COA.

Products available at EXOMA

• `/producto/aod-9604`
• `/producto/aod-9604`

All presentations are shipped with a batch COA and meet the reverse-phase HPLC purity standard. The larger-mass presentation usually offers the lowest cost per milligram.

Logistics and delivery

• Coverage. All of the Mexican Republic via courier with tracking number (AfterShip).
• Transit time. 1-4 business days depending on the region from payment confirmation.
• Shipping cost. $200 MXN de tarifa nacional única; envío gratuito en pedidos desde $2,000 MXN.
• Processing cutoff. Pedidos confirmados antes de las 16:30 (4:30 PM) hora del centro de México de lunes a viernes salen el mismo día hábil.

Additional resources

• Scientific hub: /producto/aod-9604 — variants, comparisons, studies, and full FAQ.
• Compendium: /compendio/aod-9604 — technical sheet with sequence and molecular references.
• Reconstitution calculator: /calculadora.
• Storage guide: /guia-conservacion.

This guide is educational content aimed at researchers. The information does not constitute medical advice or diagnosis. All data are reproduced for technical purposes and to support research-material procurement decisions. Bibliographic references are available on PubMed/DOI for independent verification.

References

Material for research use only. Verified primary sources supporting the scientific claims of this article:

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053183. PMID 11146367. (animal)
2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522. PMID 11713213. (animal)
3. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740. PMID 11673763. (animal)
4. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. doi:10.4021/jem157w. (humano)